MedTrace Logo

GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

NCT00716170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2013-11-28

No results posted yet for this study

Summary

In order to investigate the mechanisms underlying the hyperglucagonemia characterizing patients with type 2 diabetes mellitus (T2DM) we wish to test the following hypothesis: Do pancreatic alpha-cells exhibit inappropriate glucagon responses to substances released from the small intestine (GIP, GLP-2 and GLP-2) in patients with T2DM?

Conditions

Interventions

BIOLOGICAL

Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)

Day A: Oral glucose tolerance test (50g glucose) Day B: Isoglycemic intravenous (iv) glucose infusion Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min) Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min) Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min) Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • The Danish Medical Research Council

    collaborator OTHER

  • The Danish Diabetes Association

    collaborator OTHER

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Tina Vilsbøll, MD DMSc · Herlev Hospital

  • Filip K Knop, MD PhD · Gentofte Hospital

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716170 on ClinicalTrials.gov